Centro Diagnóstico Boris Berenstein has been acquired by DASA
The Berenstein family has sold Centro Diagnóstico Boris Berenstein (CDBB) to Diagnósticos da America S.A. (DASA).
CDBB is among the most respected and well-known diagnostic imaging services in the Brazilian northeast region, focusing on MRIs, TC scans and ultrasound exams. It has six patient service centers, distributed in four different cities in the Recife metropolitan region.
DASA is one of the leading healthcare companies in Brazil, operating the biggest diagnostics business in LatAm with a nation-wide network of high-complexity hospitals, clinics, oncology centers and other healthcare management services. DASA serves more than 20 million patients every year and has around 40,000 employees and 250,000 hired physicians.
One of Oaklins’ teams in Brazil acted as the exclusive financial advisor to the seller and the management of CDBB in the preparation of the sale process and due diligence, the approach and parallel negotiations with potential buyers, and assisted them until closing.
![](/api/deal-hero-image/107949/deal-hero-image.jpg)
![](/api/deal-party-images/107949/deal-parties.png)
![](/api/deal-client-photo/107949/deal-client-photo.jpg)
Boris Berenstein
Former Owner and President, Centro Diagnóstico Boris Berenstein
Talk to the deal team
Denis Salvador Morante
Oaklins Fortezza Partners
Related deals
Leika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn morePhen’X Technologies has sold a majority stake to Ciclad
The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.
Learn moreMedis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).
Learn more